Immunotherapy combination yields high response rate compared to earlier single-agent trials HOUSTON – A tumor-specific vaccine combined with an immune checkpoint inhibitorshrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators at The University of Texas MD Anderson Cancer Center and reported in JAMA Oncology. “That encouraging response rate is about twice the rate produced by PD1 checkpoint inhibitors in previous clinical trials, so […]
